Methods for identifying HIV neutralizing antibodies

Patent metadata

Field	Value
Publication number	US-9952218-B2
Application number	US-201314426235-A
Country	US
Kind code	B2
Filing date	Sep 6, 2013
Priority date	Sep 6, 2012
Publication date	Apr 24, 2018
Grant date	Apr 24, 2018

Abstract

The present invention relates to an in vitro method for determining HIV neutralizing antibodies in a sample. It further relates to a fusion protein to be used in said method and a nucleic acid encoding said fusion protein.

First claim

The invention claimed is:

1. An in vitro method for determining in a sample HIV neutralizing antibodies which selectively bind to the CD4 binding site of gp120, comprising:
(i) contacting a cell comprising the CD4 binding site of gp120 on its surface with the sample,
(ii) adding a fusion protein comprising (i) a protein capable of selectively binding to the CD4 binding-site of gp120 and (ii) a Fc region of a primary antibody, and
(iii) measuring, by flow cytometry, the binding efficacy of the fusion protein to the CD4 binding site of gp120,

wherein said HIV neutralizing antibodies are determined to be present in the sample if the binding of the fusion protein to the CD4 binding site of gp120 is inhibited in the presence of the sample, wherein the primary antibody is a non-human IgG or a functionally equivalent variant and wherein the HIV neutralizing antibodies recognize the CD4-binding site in gp120.

2. The method of claim 1 , wherein the protein capable of binding to the CD4 binding-site of gp120 is CD4 or a functionally equivalent variant thereof.

3. The method of claim 1 , wherein the functionally equivalent variant of CD4 is a CD4 fragment comprising at least the D1 -D2 N-terminal domains of CD4.

4. The method of claim 1 , wherein the measuring comprises using a reporter binding to the fusion protein.

5. The method of claim 1 , wherein the cell is a HIV-infected cell, and wherein the HIV-infected cell is preferably chronically infected.

6. The method of claim 1 , wherein step (ii) is preceded by at least one washing step removing unbound fusion protein.

7. The method of claim 1 , wherein the determination is a quantitative determination.

8. The method of claim 1 , wherein the sample is a plasma sample.

9. The method of claim 1 , wherein the non-human lgG is a murine lgG.

10. The method of claim 9 , wherein the murine lgG is murine lgG-1.

11. An in vitro method for the identification of an antibody-producing cell expressing HIV neutralizing antibodies, comprising:
(i) contacting a cell comprising the CD4 binding site of gp120 on its surface with a supernatant of a culture of the antibody-producing cell and with a fusion protein comprising (i) a protein capable of selectively binding to the CD4 binding-site of gp120 and (ii) an Fc region of a primary antibody, and
(ii) measuring the binding efficacy of the fusion protein to the CD4 binding site of gp120,

wherein the antibody-producing cell are determined as expressing HIV neutralizing antibodies if the binding of the fusion protein to the CD4 binding site of gp120 is inhibited in the presence of the supernatant, wherein the primary antibody is a non-human IgG or a functionally equivalent variant and wherein the HIV neutralizing antibodies recognize the CD4-binding site in gp120.

12. A method for producing HIV neutralizing antibodies, comprising:
(i) culturing antibody-producing cells isolated according to claim 11 and
(ii) isolating the antibodies expressed by the antibody-producing cells.

13. The in vitro method of claim 12 , wherein the non-human IgG is a murine IgG.

14. The method of claim 13 , wherein the murine IgG is murine IgG-1.

Assignees

• Esteve Labor Dr
• Fundacio Privada Inst De Recerca De La Sida—Caixa

Inventors

• Blanco Arbués Julián Miguel
• Carrillo Molina Jorge

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61P31/18

  for HIV · CPC title

• G01N33/56988 Primary

  HIV or HTLV · CPC title

• C07K14/005

  from viruses · CPC title

• C12N2740/16122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title